uniQure (QURE) Other Non Operating Income (2016 - 2026)
uniQure (QURE) posted quarterly Other Non Operating Income of -$16.0 million for Q2 2026, down 185.69% year-over-year from $18.6 million in Q2 2025, and down 523.72% quarter-over-quarter from $3.8 million in Q1 2026.
Analysis
uniQure (QURE) Other Non Operating Income (2016 - 2026) Analysis & Trends
uniQure's Other Non Operating Income history runs 11 years deep, the most recent figure standing at -$16.0 million for Q2 2026.
- In Q2 2026, Other Non Operating Income fell 185.69% year-over-year to -$16.0 million; the TTM figure through Jun 2026 stood at -$18.7 million (down 207.09% YoY), while the FY2025 annual figure was $26.1 million, up 348.7% from the prior year.
- Other Non Operating Income for Q2 2026 stood at -$16.0 million, down from $3.8 million in the prior quarter.
- The five-year high for Other Non Operating Income was $19.4 million in Q2 2022, with the low at -$19.1 million in Q4 2022.
- The 5-year median for Other Non Operating Income is $561500.0 (2023), against an average of $1.2 million.
- Peak annual rise in Other Non Operating Income reached 3966.67% in 2024, while the deepest fall reached 503.98% in 2024.
- uniQure's Other Non Operating Income stood at -$19.1 million in 2022, then surged by 120.66% to $3.9 million in 2023, then slumped by 503.98% to -$15.9 million in 2024, then soared by 104.7% to $749000.0 in 2025, then tumbled by 2232.18% to -$16.0 million in 2026.
- Business Quant data shows QURE's Other Non Operating Income at -$16.0 million in Q2 2026, $3.8 million in Q1 2026, and $749000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.97 Mn |
| Mar 31, 2026 | 3.77 Mn |
| Dec 31, 2025 | 749,000.00 |
| Sep 30, 2025 | -7.22 Mn |
| Jun 30, 2025 | 18.64 Mn |
| Mar 31, 2025 | 7.17 Mn |
| Dec 31, 2024 | -15.94 Mn |
| Sep 30, 2024 | 7.56 Mn |
| Jun 30, 2024 | -989,000.00 |
| Mar 31, 2024 | -1.15 Mn |
| Dec 31, 2023 | 3.95 Mn |
| Sep 30, 2023 | 186,000.00 |
| Jun 30, 2023 | 374,000.00 |
| Mar 31, 2023 | -2.37 Mn |
| Dec 31, 2022 | -19.09 Mn |
| Sep 30, 2022 | 14.36 Mn |
| Jun 30, 2022 | 19.40 Mn |
| Mar 31, 2022 | 8.57 Mn |
| Dec 31, 2021 | 8.02 Mn |
| Sep 30, 2021 | 10.44 Mn |